KALVライブシグナル | Getagraph.comで利益を最大化

買う 107839 min ago

@ $14.93

発行日: 15 2月 2024 @ 04:24

リターン: -26.16%

前回のシグナル: 2月 15 - 02:07

前回のシグナル: 売る

リターン: -1.62 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:41):

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs...

Stats
本日の出来高	51 125.00
平均出来高	817 554
時価総額	464.92M
EPS	$0 ( 2024-03-14 )
次の収益日	( $-0.690 ) 2024-07-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.53
ATR14	$0.0160 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Fairey William	Buy	17 000	Stock Option (Right to Buy)
2024-04-18	Fairey William	Buy	0
2024-03-06	Palleiko Benjamin L	Buy	250 000	Restricted Stock Unit
2024-02-20	Venrock Healthcare Capital Partners Iii, L.p.	Buy	655 738	Pre-Funded Warrants (Right to Buy)
2024-02-17	Feener Edward P.	Buy	18 788	Common Stock

INSIDER POWER
66.06
Last 98 transactions
Buy: 3 056 025 \| Sell: 628 012

ボリューム相関

長: -0.31 (neutral)

短: -0.30 (neutral)

Signal:(51.688) Neutral

Kalvista Pharmaceuticals 相関

10 最も正の相関
ACLS	0.953
BWMN	0.951
NVCN	0.949
NVAC	0.947
CRUS	0.947
TETC	0.947
XFIN	0.946
FOCS	0.944
JMAC	0.943
GENQ	0.941

10 最も負の相関
NAKD	-0.955
AMGN	-0.935
THMA	-0.932
BHTG	-0.93
LGMK	-0.926
PCSA	-0.925
AHPI	-0.924
TRIT	-0.918
CREG	-0.911
PLIN	-0.907

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kalvista Pharmaceuticals 相関 - 通貨/商品

0.63
( weak )

0.47
( neutral )

0.00
( neutral )

0.53
( weak )

0.46
( neutral )

0.01
( neutral )

Kalvista Pharmaceuticals 財務諸表

Annual	2023
収益:	$0
総利益:	$-802 000 (0.00 %)
EPS:	$-2.68

FY	2023
収益:	$0
総利益:	$-802 000 (0.00 %)
EPS:	$-2.68

FY	2022
収益:	$0
総利益:	$-743 000 (0.00 %)
EPS:	$-2.80

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.42

Financial Reports:

No articles found.

Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.